Onconova Therapeutics Inc (ONTX)

Overview

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel products aimed at treating cancer. Based in Newtown, Pennsylvania, and incorporated in 1998, the company is primarily focused on the U.S. market. Its efforts are directed towards harnessing its scientific expertise and innovative approach to create therapies that can address the unmet medical needs of cancer patients. Onconova is committed to advancing its clinical programs and bringing forth new treatments that can improve outcomes for patients suffering from various cancers.

Products and Services

• Narazaciclib:

  A multi-targeted kinase inhibitor currently being evaluated in a Phase I clinical trial. This investigational drug is being studied for its efficacy against solid tumors as well as hematological malignancies, either as a standalone therapy or in conjunction with other anti-cancer therapies. Narazaciclib's unique mechanism of action targets several pathways that are crucial for cancer cell survival and proliferation, making it a promising candidate for treating a wide spectrum of cancers.

• Oral Rigosertib:

  Another key product in Onconova’s pipeline, this compound is undergoing a Phase I/IIa study focused on progressive K-Ras mutated non-small cell lung cancer. The study is exploring the efficacy of oral rigosertib both as a monotherapy and in combination with a PD-1 inhibitor. PD-1 inhibitors are part of a class of drugs known as checkpoint inhibitors, which work by unleashing the immune system to fight cancer cells. The combination of oral rigosertib with these immunotherapies could potentially offer a new treatment avenue for patients with this challenging form of lung cancer.

• Rigosertib Monotherapy for Squamous Cell Carcinoma:

  In addition to the studies mentioned above, Onconova is conducting a Phase II investigator-initiated study evaluating rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. This study highlights the company’s commitment to exploring the potential benefits of its drugs across various cancer types, particularly in rare and difficult-to-treat conditions.

Onconova has entered into a license and collaboration agreement with HanX Biopharmaceuticals, Inc., focusing on the development, registration, and commercialization of narazaciclib in China. This partnership exemplifies the company's strategy to expand its global footprint and explore new markets for its innovative cancer therapies.